Capital Planning Advisors Upped Lilly Eli & Co (LLY) Stake By $405,790; Biospecifics Technologies (BSTC) Has 1.08 Sentiment

January 16, 2018 - By Adrian Erickson

BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for multiple indications in the United States. The company has market cap of $316.68 million. The firm offers injectable collagenase for the treatment of DupuytrenÂ’s contracture and PeyronieÂ’s disease under the XIAFLEX brand in Canada and Australia, as well as under XIAPEX brand name in Europe. It has a 27.7 P/E ratio. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, and plantar fibromatosis, as well as for the treatment of human lipoma and uterine fibroids.

Capital Planning Advisors Llc increased Lilly Eli & Co (LLY) stake by 91.75% reported in 2017Q3 SEC filing. Capital Planning Advisors Llc acquired 4,774 shares as Lilly Eli & Co (LLY)’s stock declined 3.22%. The Capital Planning Advisors Llc holds 9,977 shares with $853,000 value, up from 5,203 last quarter. Lilly Eli & Co now has $89.83B valuation. The stock decreased 1.38% or $1.2 during the last trading session, reaching $85.78. About 1.85M shares traded. Eli Lilly and Company (NYSE:LLY) has risen 4.70% since January 16, 2017 and is uptrending. It has underperformed by 12.00% the S&P500.

Jw Asset Management Llc holds 2.51% of its portfolio in BioSpecifics Technologies Corp. for 73,649 shares. Northpointe Capital Llc owns 135,657 shares or 0.67% of their US portfolio. Moreover, Elk Creek Partners Llc has 0.5% invested in the company for 170,102 shares. The California-based Rice Hall James & Associates Llc has invested 0.32% in the stock. Ativo Capital Management Llc, a Illinois-based fund reported 22,592 shares.

The stock increased 2.61% or $1.12 during the last trading session, reaching $44.05. About 5,362 shares traded. BioSpecifics Technologies Corp. (BSTC) has risen 49.91% since January 16, 2017 and is uptrending. It has outperformed by 33.21% the S&P500.

Analysts await BioSpecifics Technologies Corp. (NASDAQ:BSTC) to report earnings on March, 21. They expect $0.39 EPS, down 2.50% or $0.01 from last year’s $0.4 per share. BSTC’s profit will be $2.80M for 28.24 P/E if the $0.39 EPS becomes a reality. After $0.37 actual EPS reported by BioSpecifics Technologies Corp. for the previous quarter, Wall Street now forecasts 5.41% EPS growth.

Since August 31, 2017, it had 0 buys, and 6 selling transactions for $83.39 million activity. $15.68M worth of Eli Lilly and Company (NYSE:LLY) was sold by LILLY ENDOWMENT INC. $1.08 million worth of Eli Lilly and Company (NYSE:LLY) was sold by Simmons Jeffrey N.

Among 20 analysts covering Eli Lilly and Company (NYSE:LLY), 13 have Buy rating, 1 Sell and 6 Hold. Therefore 65% are positive. Eli Lilly and Company had 89 analyst reports since July 23, 2015 according to SRatingsIntel. On Wednesday, December 13 the stock rating was maintained by Leerink Swann with “Hold”. On Thursday, November 12 the stock rating was maintained by Leerink Swann with “Outperform”. The firm has “Hold” rating by Argus Research given on Thursday, April 27. Cowen & Co maintained it with “Outperform” rating and $92 target in Saturday, August 22 report. Credit Suisse maintained the stock with “Hold” rating in Wednesday, December 13 report. Deutsche Bank upgraded it to “Buy” rating and $99 target in Monday, December 7 report. The rating was maintained by Jefferies on Thursday, June 22 with “Buy”. The company was maintained on Monday, July 17 by Jefferies. The company was maintained on Monday, October 16 by Jefferies. The stock of Eli Lilly and Company (NYSE:LLY) has “Hold” rating given on Thursday, August 31 by Leerink Swann.

Investors sentiment decreased to 0.89 in 2017 Q3. Its down 0.01, from 0.9 in 2017Q2. It is negative, as 66 investors sold LLY shares while 386 reduced holdings. 79 funds opened positions while 325 raised stakes. 827.83 million shares or 0.59% more from 823.00 million shares in 2017Q2 were reported. Mutual Of Omaha Financial Bank Wealth Management invested 0.14% of its portfolio in Eli Lilly and Company (NYSE:LLY). Torch Wealth Management Lc accumulated 11,275 shares or 0.63% of the stock. Winslow Asset Management Inc, a Ohio-based fund reported 66,964 shares. Greenleaf owns 6,146 shares for 0.01% of their portfolio. 90,330 were reported by Twin Cap Mgmt. Old National State Bank In holds 735,489 shares or 3.42% of its portfolio. Iguana Health Mngmt Limited Com accumulated 40,000 shares or 1.91% of the stock. Voya Invest Mgmt Limited Liability Corporation reported 0.1% of its portfolio in Eli Lilly and Company (NYSE:LLY). South State Corporation holds 30,201 shares or 0.29% of its portfolio. Mu Invs Ltd accumulated 410 shares. Wheatland Advsr Inc reported 29,230 shares stake. Carret Asset Mgmt Ltd Co has 7,850 shares. 18,796 are held by Foster Dykema Cabot Inc Ma. Wealth Enhancement Advisory Serv Ltd Com has invested 0.08% in Eli Lilly and Company (NYSE:LLY). Natixis stated it has 0.3% of its portfolio in Eli Lilly and Company (NYSE:LLY).

Capital Planning Advisors Llc decreased Pfizer Inc (NYSE:PFE) stake by 37,686 shares to 77,190 valued at $2.76M in 2017Q3. It also reduced General Electric Co (NYSE:GE) stake by 94,461 shares and now owns 12,263 shares. Altria Group Inc (NYSE:MO) was reduced too.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: